An interventional study of Motor Control Exercise + Myofascial Release and Motor Control Exercise in Greater Trochanteric Pain Syndrome, sponsored by Harran University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Harran University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,720 studies in Pain with a site in Turkey — 323 open to participants now, 376 under way, none of them phase 3. Pain · Turkey.
Among the 1,720 studies in Pain with a site in Turkey, this one is the 680th largest by planned enrollment of the 1,497 interventional ones that give a count, is one of 184 that started in 2026, is one of 1,455 with no phase, reaches primary completion later than 279 of the 375 other live ones, and was the 1,648th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →323 of the 1,720 studies in Pain with a site in Turkey are open now. Recruiting first, the newest first:
Mersin University · Sites in Turkey
Ages 18+
Artvin Coruh University · Sites in Turkey
Ages 6–12
Mersin University · Sites in Turkey
Ages 18+
Bahçeşehir University · Sites in Turkey
Ages 45–65
Istanbul University · Sites in Turkey
Ages 1–12
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,720 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6 · Phase 4 34
First in 2006; this study’s year is marked. 184 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 70 across the 1,497 interventional studies, 84 across the 223 observational. Of the 1,272 that completed or were terminated, 7 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 1,720 have an industry lead sponsor. The 10 most frequent:
Harran University is the lead sponsor of 64 studies on the registry; 22 are open to participants now.
Harran University has 7 studies filed under Pain — fewer than ten, so there is no comparison to draw.
88 of the studies in Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846098Cumhuriyet UniversityComparison of Intraosseous Anesthesia and Inferior Alveolar Nerve Block for Primary Mandibular Molars | 2026-11-20 |
| NCT07404163Tarsus UniversityWalkway Used in Postoperative Mobilization | 2026-11-30 |
| NCT07915804Istanbul UniversityPerfusion Index for Postoperative Pain Assessment in Pediatric Adenotonsillectomy | 2026-11-30 |
| NCT07892196Antalya Training and Research HospitalDoes Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy? | 2026-11-30 |
| NCT07936604Harran UniversityMotor Control Exercise and Myofascial Release in Greater Trochanteric Pain Syndrome | 2026-11-30 |
Add all 88 to your calendar (.ics) → With an account.
Among the 1,720 studies in Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Greater Trochanteric Pain Syndrome (GTPS) is a common musculoskeletal condition associated with lateral hip pain, impaired muscle function, and reduced physical performance. This randomized controlled trial aims to investigate the effects of motor control exercises combined with myofascial release techniques on pain intensity, pain threshold, muscle activation patterns, muscle strength, functional capacity, quality of life, and gait parameters in individuals diagnosed with GTPS.
A total of 72 participants with GTPS will be randomly allocated to one of three groups: (1) motor control exercises combined with myofascial release techniques, (2) motor control exercises alone, or (3) a control group receiving a home-based motor control exercise program in brochure format. Outcome measures will be assessed at baseline and after an 8-week intervention period. The results of this study may provide evidence for optimizing rehabilitation strategies for individuals with GTPS.
Greater Trochanteric Pain Syndrome (GTPS) is a clinical condition that encompasses disorders affecting the trochanteric bursa (trochanteric bursitis) and the gluteus medius and minimus tendons (gluteal tendinopathy). Individuals with GTPS commonly experience intermittent or persistent lateral hip pain around the greater trochanter, which may substantially impair daily functioning. Symptoms are often aggravated by side-lying, stair climbing, walking, transitioning from sitting to standing, and physical activity.
The primary objective of this randomized controlled trial is to evaluate the effects of motor control exercises combined with myofascial release techniques on GTPS-related symptoms, including pain intensity, pain threshold, and muscle activation patterns, as well as functional outcomes such as muscle strength, Harris Hip Score (HHS), Lower Extremity Functional Scale (LEFS), Short Form-36 (SF-36), Timed Up and Go Test (TUG), Stair Climb Test (SCT), and gait parameters.
A total of 72 participants diagnosed with GTPS will be randomly assigned to one of three groups: (1) a motor control exercise plus myofascial release group, (2) a motor control exercise group, or (3) a control group receiving a home-based motor control exercise brochure. Outcomes will be assessed at baseline and after an 8-week intervention period. The findings may contribute to the development of more effective rehabilitation strategies for individuals with GTPS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional criterion for post-surgical participants:
- Diagnosed with GTPS at least 12 months after hip arthroplasty surgery
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a motor control exercise program combined with myofascial release techniques for 8 weeks.
Procedure: Motor Control Exercise + Myofascial Release
Participants will receive a motor control exercise program for 8 weeks.
Procedure: Motor Control Exercise
Participants will receive a home-based motor control exercise program in brochure format for 8 weeks.
Procedure: Home Exercise Program
Participants will receive a motor control exercise program combined with myofascial release techniques for 8 weeks.
Participants will receive a motor control exercise program for 8 weeks.
Participants will receive a home-based motor control exercise program in brochure format for 8 weeks.
Short-Form McGill Pain Questionnaire -Pain Rating Index
Pain characteristics and severity will be assessed using the 15-item Pain Rating Index of the Short-Form McGill Pain Questionnaire (SF-MPQ). Each item is scored from 0 (none) to 3 (severe), resulting in a total score ranging from 0 to 45. Higher scores indicate greater pain severity and a worse outcome.
Time frame: Baseline and 8 weeks after intervention
Short-Form McGill Pain Questionnaire - Present Pain Intensity
Current pain intensity will be assessed using the Present Pain Intensity (PPI) component of the Short-Form McGill Pain Questionnaire (SF-MPQ). Scores range from 0 (no pain) to 5 (excruciating pain), with higher scores indicating greater current pain intensity and a worse outcome.
Time frame: Baseline and 8 weeks after intervention
Short-Form McGill Pain Questionnaire - Visual Analog Scale
Pain intensity will be assessed using the Visual Analog Scale (VAS) included in the Short-Form McGill Pain Questionnaire (SF-MPQ). The scale ranges from 0 to 10 mm, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity and a worse outcome.
Time frame: Baseline and 8 weeks after intervention
Gluteus Medius Pressure Pain Threshold
Pressure pain threshold of the gluteus medius muscle will be measured using a digital algometer. Measurements will be recorded in pounds-force (lbf). Three measurements will be performed, and their arithmetic mean will be calculated. Higher values indicate a higher pressure pain threshold and lower sensitivity to pressure-induced pain.
Time frame: Baseline and 8 weeks after intervention
Tensor Fasciae Latae Pressure Pain Threshold
Pressure pain threshold of the tensor fasciae latae muscle will be measured using a digital algometer. Measurements will be recorded in pounds-force (lbf). Three measurements will be performed, and their arithmetic mean will be calculated. Higher values indicate a higher pressure pain threshold and lower sensitivity to pressure-induced pain.
Time frame: Baseline and 8 weeks after intervention
Gluteus Medius Muscle Activation During Mini Squat
Gluteus medius muscle activation during mini squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.
Time frame: Baseline and 8 weeks after intervention
Gluteus Medius Muscle Activation During Single-Leg Squat
Gluteus medius muscle activation during single-leg squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.
Time frame: Baseline and 8 weeks after intervention
Tensor Fasciae Latae Muscle Activation During Mini Squat
Tensor fasciae latae muscle activation during mini squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.
Time frame: Baseline and 8 weeks after intervention
Tensor Fasciae Latae Muscle Activation During Single-Leg Squat
Tensor fasciae latae muscle activation during single-leg squat will be evaluated using surface electromyography (sEMG). EMG activity will be normalized to the corresponding maximum voluntary contraction (MVC) value and expressed as a percentage of MVC (%MVC). Three measurements will be performed, and their mean value will be calculated. Higher values indicate greater muscle activation relative to MVC.
Time frame: Baseline and 8 weeks after intervention
Hip Abductor Muscle Strength
Hip abductor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip abductor muscle strength.
Time frame: Baseline and 8 weeks after intervention
Hip Flexor Muscle Strength
Hip flexor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip flexor muscle strength.
Time frame: Baseline and 8 weeks after intervention
Hip Extensor Muscle Strength
Hip extensor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip extensor muscle strength.
Time frame: Baseline and 8 weeks after intervention
Hip Internal Rotator Muscle Strength
Hip internal rotator muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip internal rotator muscle strength.
Time frame: Baseline and 8 weeks after intervention
Hip External Rotator Muscle Strength
Hip external rotator muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater hip external rotator muscle strength.
Time frame: Baseline and 8 weeks after intervention
Tensor Fasciae Latae Muscle Strength
Tensor fasciae latae muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contraction. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater muscle strength in the tested position.
Time frame: Baseline and 8 weeks after intervention
Knee Flexor Muscle Strength
Knee flexor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater knee flexor muscle strength.
Time frame: Baseline and 8 weeks after intervention
Knee Extensor Muscle Strength
Knee extensor muscle strength will be assessed using a handheld dynamometer during maximal voluntary isometric contractions. Measurements will be expressed in Newtons (N). Three consecutive measurements will be performed, and their arithmetic mean will be used for analysis. Higher values indicate greater knee extensor muscle strength.
Time frame: Baseline and 8 weeks after intervention
Harris Hip Score
Hip-related pain and functional status will be assessed using the Harris Hip Score. The total score ranges from 0 to 100, with higher scores indicating better hip function and less pain.
Time frame: Baseline and 8 weeks after intervention
Lower Extremity Functional Scale
Functional limitations related to lower extremity disorders will be evaluated using Lower Extremity Functional Scale. The total score ranges from 0 to 80, with higher scores indicating better lower extremity function and fewer functional limitations.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 Physical Functioning
Physical functioning will be assessed using the Physical Functioning domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better physical functioning.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 Role Limitations Due to Physical Health
Role limitations due to physical health problems will be assessed using the Role Physical domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating fewer limitations due to physical health problems.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 Bodily Pain
Bodily pain will be assessed using the Bodily Pain domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating less pain and less pain-related interference.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 General Health
General health perceptions will be assessed using the General Health domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better perceived general health.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 Vitality
Vitality will be assessed using the Vitality domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating greater vitality and less fatigue.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 Social Functioning
Social functioning will be assessed using the Social Functioning domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better social functioning.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 Role Limitations Due to Emotional Problems
Role limitations due to emotional problems will be assessed using the Role Emotional domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating fewer limitations due to emotional problems.
Time frame: Baseline and 8 weeks after intervention
Short Form- 36 Mental Health
Mental health will be assessed using the Mental Health domain of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better mental health.
Time frame: Baseline and 8 weeks after intervention
Timed Up and Go Test
Functional mobility will be assessed using the Timed Up and Go Test. The time required to stand up from a chair, walk 3 meters, turn around, walk back, and sit down will be recorded in seconds. Lower values indicate better functional mobility and performance.
Time frame: Baseline and 8 weeks after intervention
Stair Climb Test
Functional stair-climbing performance will be assessed using the Stair Climb Test. The time required to ascend and descend a standardized flight of stairs will be recorded in seconds. Lower values indicate better stair-climbing performance and functional mobility.
Time frame: Baseline and 8 weeks after intervention
Gait Parameters- Stride Length
Stride length will be evaluated using a powdered ground walking analysis method. The distance between two consecutive footprints of the same foot will be measured in centimeters (cm). Higher values indicate greater stride length.
Time frame: Baseline and 8 weeks after intervention
Gait Parameters-Step Width
Step width will be evaluated using a powdered ground walking analysis method. The mediolateral distance between successive footprints will be measured in centimeters (cm). Higher values indicate greater step width.
Time frame: Baseline and 8 weeks after intervention
Gait Parameters- Cadence
Gait cadence will be evaluated during walking using a powdered ground walking analysis method, with the number of steps and elapsed walking time recorded. Cadence will be calculated as the number of steps taken per minute (steps/min). Higher values indicate greater stepping frequency.
Time frame: Baseline and 8 weeks after intervention
Plan to share: No — Individual participant data (IPD) will not be shared because the study involves confidential participant health information and no data-sharing plan has been established.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.
Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 3 months is below that.
Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Harran University